Hovione accesses micellar technology
Hovione has signed an agreement with Dragonfly Technologies to gain access to its micellar technology for chemistry-in-water processes, developed by Professor Bruce Lipshutz of the University of California, Santa Barbara. The company said that it will develop the technology to become an integral part of its API manufacturing technology offering.
Micellar chemistry enables multiple chemical transformations to take place in nanomicelles dispersed in water, mimicking natural chemical transformations. By using it, reactions can tale place at lower temperatures with lower volumes or even no metal catalysts. It can also mininise the use of organic solvents.
RELATED ARTICLES
Two CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
CatSci has opened a second oligonucleotides laboratory, which it will use “to introduce novel workflows for the rapid production of vast numbers of oligos at a scale optimised for rapid screening”.
Swedish-based CDMO Recipharm announced at CPHI that it is “expanding its pharmaceutical development capabilities through targeted investments and the integration of cutting-edge technologies”.
